Talk:Targeted therapy

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Medicine / Hematology-oncology (Rated C-class, Mid-importance)
WikiProject icon This article is within the scope of WikiProject Medicine, which recommends that this article follow the Manual of Style for medicine-related articles and use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
C-Class article C  This article has been rated as C-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.
Taskforce icon
This article is supported by the Hematology-oncology task force.

Progress and future[edit]

The mention of only cannabidiol seems unbalanced. It might be better if we could list targeted therapies in say phase III clinical trials here (if there is no better place) ? Rod57 (talk) 05:57, 28 November 2008 (UTC)

How about just deleting the example entirely? Adding an example (any example) doesn't really help the reader understand the concept in this case. (I'm not sure that the cannabidiol example is actually accurate. It sounds like it's just low-side-effects systemic therapy.) WhatamIdoing (talk) 02:59, 2 December 2008 (UTC)
Agreed on all points - it is a systemic therapy, removed. Rdbbbbbb (talk) 19:01, 5 April 2010 (UTC)
Happy with removal, but not sure a systemic therapy can't also be aimed at a molecular target. Rod57 (talk) 15:53, 14 February 2011 (UTC)
Should Synta Pharma's ganetespib now be cited in the Small Molecule section? Ganetespib is a unique Triazolone-containing Hsp90 inhibitor, now in phase 2/3 NSCLC trials. If my reading of recent reports is correct, this drug is showing rather considerable promise: ("STA-9090"&rank=15): efficacy with no ocular or renal toxicity in sizable targeted groups of patients with late stage lung carcinomas that have been unresponsive to other therapies. Ganetespib is a potent inhibitor of Hsp90, structurally unrelated to first-generation ansamycin-family Hsp90 inhibitors, being evaluated in 20+ clinical trials, either ongoing, or initiating, with the most advanced being the Phase 2b/3 GLAXAY trial evaluating ganetespib with docetaxel vs docetaxel alone in patients with advanced NSCLC who have progressed on first-line therapy. A global trial evaluating single-agent ganetespib in approximately 100 patients with ALK+ NSCLC who have not been previously treated with an ALK inhibitor is in the process of initiating. Frankatca (talk) 16:37, 6 March 2012 (UTC)
Targeted therapies lists so many FDA approved ones that it seems a distraction to try to list individual unapproved/experimental ones. It seems worth mentioning major categories in late stage clinical trials. I'm not sure salinomycin has a molecular target to qualify as a TT even if ever approved. - Rod57 (talk) 20:25, 12 October 2012 (UTC)

Only for cancer ?[edit]

The intro implies they are [only] for cancer. Can 'targeted therapy' not be used for say a targeted treatment for rheumatoid arthritis ? — Preceding unsigned comment added by Rod57 (talkcontribs) 15:35, 14 February 2011

In theory, it's possible for any type of disease. In practice, all of the examples I can think of offhand are—or were originally intended for—treatment of cancer. WhatamIdoing (talk) 19:18, 15 February 2011 (UTC)